Search - tctmd.com

Displaying 221 - 240 of 329

Sort: Relevancy | Date

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation TCT 2016

Impact of LAA Exclusion on Neurohormonal Modulation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation: Scope of the Problem

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michael D. Ezekowitz

October 30, 2016

Presentation TCT 2016

TAVR in Patients With Atrial Fibrillation

Presenter: Neal S. Kleiman, Patrick T. O'Gara, Fabian Nietlispach

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx

October 30, 2016

Presentation TCT 2015

Incidence, Significance, and Management of New-Onset Atrial Fibrillation After TAVR

Presenter: Isaac George, Augusto D. Pichard, Alec S. Vahanian

October 15, 2015

Presentation TCT 2015

Miscellaneous Emerging Technologies 4: Stent-Based Pulmonary Vein Isolation Approach to Atrial Fibrillation

Presenter: Greg L. Kaluza, Joachim Schofer, Glenn Van Langenhove

October 15, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

Presentation TCT 2015

Putting It All Together: How to Manage the Patient With Atrial Fibrillation Undergoing PCI

Presenter: Gerhard C. Schuler, Matthew J. Price

October 14, 2015

Presentation TCT 2015

Considerations Regarding Renal Function in the Patient With Atrial Fibrillation

Presenter: Gerhard C. Schuler, C. Michael Gibson

October 14, 2015

Presentation TCT 2015

Device-Detected, Subclinical Atrial Fibrillation: Now What?

Presenter: Gerhard C. Schuler, Freek W.A. Verheugt

October 14, 2015

Presentation TCT 2015

Alternatives to Anticoagulation: Left Atrial Appendage Occlusion Devices

Presenter: Gerhard C. Schuler, Matthew J. Price

October 14, 2015

Presentation TCT 2015

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Roxana Mehran

October 14, 2015

Presentation TCT 2015

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Deepak L. Bhatt

October 14, 2015

Presentation TCT 2015

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Pascal Vranckx, Renato D. Lopes

October 14, 2015

Presentation TCT 2015

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Presenter: Pascal Vranckx, Freek W.A. Verheugt

October 14, 2015

Presentation TCT 2015

Reversal Agents for Factor Xa Inhibitors

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2015

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe, Manesh R. Patel

October 14, 2015

Presentation TCT 2015

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Advertisement

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Impact of LAA Exclusion on Neurohormonal Modulation

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Atrial Fibrillation: Scope of the Problem

TAVR in Patients With Atrial Fibrillation

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Incidence, Significance, and Management of New-Onset Atrial Fibrillation After TAVR

Miscellaneous Emerging Technologies 4: Stent-Based Pulmonary Vein Isolation Approach to Atrial Fibrillation

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Putting It All Together: How to Manage the Patient With Atrial Fibrillation Undergoing PCI

Considerations Regarding Renal Function in the Patient With Atrial Fibrillation

Device-Detected, Subclinical Atrial Fibrillation: Now What?

Alternatives to Anticoagulation: Left Atrial Appendage Occlusion Devices

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Reversal Agents for Factor Xa Inhibitors

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content